•  
  •  
  •  
  •  

2026-07-20 06:26:53

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality
  • Bhansali Engineering Polymers Limited Marks Strong Start to FY27: Q1 Consolidated Net Profit Surges 42.9% to ₹65.60 Crore
  • Sangam India Ltd Reports Surge in Q1 FY27 Net Profit to ₹4,102 Lakhs
  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million

Keywords Selected:  ANDa

Research

  • India Inc revenue growth likely moderated to 4-6% in March quarter - CRISIL Market Intelligence and Analytics

Stock Report

  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Concord Biotech Ltd successfully completes PPB and NDA inspection
  • Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg
  • Concord Biotech Ltd receives ANDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Levothyroxine Sodium Tablets USP
  • Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
  • Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Semaglutide Injection, supported by OneSource as CDMO partner
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Marksans Pharma Ltd receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg
  • Caplin Steriles gets USFDA approval for Sodium Phosphates Injection
  • Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • B and A Ltd consolidated Q2FY26 net profit at Rs. 25.49 crores
  • Caplin Steriles Ltd receives USFDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection

Latest Post

  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality
  • Bhansali Engineering Polymers Limited Marks Strong Start to FY27: Q1 Consolidated Net Profit Surges 42.9% to ₹65.60 Crore
  • Sangam India Ltd Reports Surge in Q1 FY27 Net Profit to ₹4,102 Lakhs
  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025